Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropinirole
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ropinirole is a small molecule pharmaceutical drug classified as a dopamine agonist. It is used alone or with other medications to treat the symptoms of Parkinson's disease, such as tremors, stiffness, slowed movements, and balance problems. Ropinirole is also indicated for the treatment of restless legs syndrome (RLS), a neurological disorder characterized by uncomfortable sensations in the legs and an urge to move them. The drug works by mimicking the action of dopamine in the brain, compensating for low levels of this neurotransmitter that are associated with both Parkinson's disease and RLS[1][2][3][5].
- Brand names
- RequipRequip XLRepreve
- Other names
- ropinirolumropinirol (INN-Spanish)RopitorNarapin
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)
Beyond the preview
Go deeper on ropinirole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropinirole.